Filing Details
- Accession Number:
- 0001645470-19-000027
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-29 16:52:57
- Reporting Period:
- 2019-04-26
- Accepted Time:
- 2019-04-29 16:52:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1528172 | Endonovo Therapeutics Inc. | ENDV | Pharmaceutical Preparations (2834) | 452552528 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1645470 | Brian Alan Collier | 6320 Canoga Avenue 15Th Floor Woodland Hills CA 91367 | Ceo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-04-26 | 2,000 | $0.01 | 21,120,123 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-04-26 | 5,000 | $0.01 | 21,125,123 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-04-26 | 10,000 | $0.01 | 21,135,123 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-04-26 | 10,000 | $0.01 | 21,145,123 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-04-26 | 2,000 | $0.02 | 21,147,123 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-04-26 | 5,000 | $0.01 | 21,152,123 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-04-29 | 2,000 | $0.02 | 21,154,123 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-04-29 | 2,000 | $0.02 | 21,156,123 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-04-29 | 2,000 | $0.01 | 21,158,123 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |